Cuthbert Alan W
Dept of Medicine, University of Cambridge, Addenbrooke's Hospital, CB2 2QQ, Cambridge, UK.
Trends Pharmacol Sci. 2002 Nov;23(11):504-9. doi: 10.1016/s0165-6147(02)02094-1.
Completion of the human genome project raises the possibility of genetically based treatments for a multitude of human diseases. As yet only a handful of patients have benefited clinically from this approach. Why gene transfer is such a complex issue is discussed in this article. Theoretically, the easiest diseases to treat are single gene recessive diseases, where, presumably, gene delivery to somatic cells is all that is required. Two prime candidates for gene therapy are severe combined immunodeficiency disease (SCID) and cystic fibrosis (CF). Attempts to treat both of these diseases by gene therapy commenced in the late 1980s. Some clinical benefit has been recorded with SCID, but none, as yet, has been recorded with CF.
人类基因组计划的完成增加了针对多种人类疾病进行基因治疗的可能性。到目前为止,只有少数患者从这种方法中获得了临床益处。本文讨论了为什么基因转移是一个如此复杂的问题。从理论上讲,最容易治疗的疾病是单基因隐性疾病,据推测,将基因导入体细胞就足够了。基因治疗的两个主要候选对象是重症联合免疫缺陷病(SCID)和囊性纤维化(CF)。20世纪80年代末开始尝试用基因疗法治疗这两种疾病。治疗SCID已记录到一些临床益处,但治疗CF尚未记录到任何益处。